Literature DB >> 22445462

Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes.

Mónica Martínez-Cengotitabengoa1, Karina Soledad Mac-Dowell, Juan Carlos Leza, Juan Antonio Micó, Miryam Fernandez, Enrique Echevarría, Julio Sanjuan, Julián Elorza, Ana González-Pinto.   

Abstract

INTRODUCTION: This study measures the levels of various markers of oxidative stress and inflammation in blood samples from first-episode psychosis (FEP) patients, and examines the association between these peripheral biomarkers and cognitive performance at 6 months after treatment.
METHODS: Twenty-eight FEP patients and 28 healthy controls (matched by age, sex and educational level) had blood samples taken at admission for assessment of total antioxidant status, superoxide dismutase (SOD), total glutathione (GSH), catalase (CAT), glutathione peroxidase, lipid peroxidation, nitrites and the chemokine monocyte chemoattractant protein-1 (MCP-1). A battery of cognitive tests was also applied to the healthy controls and those FEP patients who were in remission at 6 months after the acute episode.
RESULTS: FEP patients had significantly lower levels of total antioxidant status, catalase and glutathione peroxidase, compared with the healthy controls. Regression analyses found that MCP-1 levels were negatively associated with learning and memory (verbal and working), nitrite levels were negatively associated with executive function, and glutathione levels were positively associated with executive function.
CONCLUSION: Our results suggest an association between certain peripheral markers of oxidative stress and inflammation and specific aspects of cognitive functioning in FEP patients. Further studies on the association between MCP-1 and cognition are warranted.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445462     DOI: 10.1016/j.schres.2012.03.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  31 in total

Review 1.  Oxidative stress and schizophrenia: recent breakthroughs from an old story.

Authors:  Francesco E Emiliani; Thomas W Sedlak; Akira Sawa
Journal:  Curr Opin Psychiatry       Date:  2014-05       Impact factor: 4.741

2.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 3.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

4.  N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges.

Authors:  Twanette Swanepoel; Marisa Möller; Brian Herbert Harvey
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

5.  Activated Phosphorylated STAT1 Levels as a Biologically Relevant Immune Signal in Schizophrenia.

Authors:  Rajiv P Sharma; Cherise Rosen; Jennifer K Melbourne; Benjamin Feiner; Kayla A Chase
Journal:  Neuroimmunomodulation       Date:  2016-11-08       Impact factor: 2.492

6.  Abnormalities in chemokine levels in schizophrenia and their clinical correlates.

Authors:  Suzi Hong; Ellen E Lee; Averria Sirkin Martin; Benchawanna Soontornniyomkij; Virawudh Soontornniyomkij; Cristian L Achim; Chase Reuter; Michael R Irwin; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-09-17       Impact factor: 4.939

7.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 8.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

9.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

10.  Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Authors:  Donald C Goff
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.